More than 65% of participants reached an A1C level below 6.5%. Orforglipron is the first small-molecule GLP-1 therapy to successfully complete a phase 3 trial. Eli Lilly plans to submit for ...

Eli Lilly announced Thursday the successful completion of a phase 3 trial of Orforglipron – the first small-molecule GLP-1 that is administered as a once-daily oral pill. The ACHIEVE-1 trial ...

Over the past decade, the global pharmaceutical industry has witnessed a transformation in the treatment landscape for ...

Regeneron’s shares have declined nearly 17% following the failure of the company’s Dupixent follow-up itepekimab.

Eli Lilly's solution was to ditch peptides and find an incredibly small molecule to mimic them, which can bind to the same "pocket" on the GLP-1 receptor that the peptides would target.

Eli Lilly joins up with Camurus to make long-acting versions of the pharma's obesity and diabetes drugs, joining the industry ...

Discover how the breakthrough pill orforglipron matches injectable weight loss drugs in effectiveness while offering ...